Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Clinical depression in untreated obstructive sleep apnea: examining predictors and a meta-analysis of prevalence rates.

Jackson ML, Tolson J, Bartlett D, Berlowitz DJ, Varma P, Barnes M.

Sleep Med. 2019 Oct;62:22-28. doi: 10.1016/j.sleep.2019.03.011. Epub 2019 Mar 27.

PMID:
31525678
2.

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.

Mak G, Soria JC, Blagden SP, Plummer R, Fleming RA, Nebot N, Zhang J, Mazumdar J, Rogan D, Gazzah A, Rizzuto I, Greystoke A, Yan L, Tolson J, Auger KR, Arkenau HT.

Br J Cancer. 2019 May;120(10):975-981. doi: 10.1038/s41416-019-0452-3. Epub 2019 Apr 17.

3.

Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Tolson JM, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE.

Neurology. 2019 Mar 12;92(11):543. doi: 10.1212/WNL.0000000000007085. No abstract available.

PMID:
30858245
4.

Communication in a crisis in UK ambulance services: What is needed to improve incident communication?

Tovey O, Tolson J, Vinand A.

J Bus Contin Emer Plan. 2018 Jan 1;11(4):309-316.

PMID:
30670132
5.

Apnoea and hypopnoea scoring for people with spinal cord injury: new thresholds for sleep disordered breathing diagnosis and severity classification.

Schembri R, Graco M, Spong J, Ruehland WR, Tolson J, Rochford PD, Duce B, Stevens B, Berlowitz DJ.

Spinal Cord. 2019 May;57(5):372-379. doi: 10.1038/s41393-018-0229-1. Epub 2019 Jan 9.

PMID:
30626976
6.

Worth the effort? Weighing up the benefit and burden of continuous positive airway pressure therapy for the treatment of obstructive sleep apnoea in chronic tetraplegia.

Graco M, Green SE, Tolson J, Stevens B, Barnes M, Rigoni A, Henderson S, Nicholls C, Berlowitz DJ.

Spinal Cord. 2019 Mar;57(3):247-254. doi: 10.1038/s41393-018-0210-z. Epub 2018 Oct 24.

PMID:
30356181
7.

A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.

Brown NF, Williams M, Arkenau HT, Fleming RA, Tolson J, Yan L, Zhang J, Swartz L, Singh R, Auger KR, Lenox L, Cox D, Lewis Y, Plisson C, Searle G, Saleem A, Blagden S, Mulholland P.

Neuro Oncol. 2018 Nov 12;20(12):1634-1642. doi: 10.1093/neuonc/noy078.

8.

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.

Bar-Or A, Grove RA, Austin DJ, Tolson JM, VanMeter SA, Lewis EW, Derosier FJ, Lopez MC, Kavanagh ST, Miller AE, Sorensen PS.

Neurology. 2018 May 15;90(20):e1805-e1814. doi: 10.1212/WNL.0000000000005516. Epub 2018 Apr 25. Erratum in: Neurology. 2018 Sep 11;91(11):538.

9.

Out of the blue: Blue blood.!

Elakkumanan LB, Cherukat J, Tolson JN, Sistla S, Basavarajegowda A.

Asian J Transfus Sci. 2017 Jul-Dec;11(2):212. doi: 10.4103/ajts.AJTS_75_16. No abstract available.

10.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.

Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT.

Clin Cancer Res. 2017 Oct 1;23(19):5981-5992. doi: 10.1158/1078-0432.CCR-17-0725. Epub 2017 Jun 23.

11.

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

McLaughlin V, Channick RN, Ghofrani HA, LemariƩ JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM.

Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.

12.

Patients' estimates of their sleep times: reliability and impact on diagnosis of obstructive sleep apnoea.

Khor YH, Tolson J, Churchward T, Rochford P, Worsnop C.

Intern Med J. 2015 Aug;45(8):850-3. doi: 10.1111/imj.12798.

PMID:
25944502
13.

Microbial risk assessment for recreational use of the Chicago area waterway system.

Rijal G, Tolson JK, Petropoulou C, Granato TC, Glymph A, Gerba C, Deflaun MF, O'Connor C, Kollias L, Lanyon R.

J Water Health. 2011 Mar;9(1):169-86. doi: 10.2166/wh.2010.020.

PMID:
21301125
14.

A 52-week study of gabapentin enacarbil in restless legs syndrome.

Ellenbogen AL, Thein SG, Winslow DH, Becker PM, Tolson JM, Lassauzet ML, Chen D.

Clin Neuropharmacol. 2011 Jan-Feb;34(1):8-16. doi: 10.1097/WNF.0b013e3182087d48.

PMID:
21242741
15.

Dry and wet weather microbial characterization of the Chicago area waterway system.

Rijal G, Petropoulou C, Tolson JK, DeFlaun M, Gerba C, Gore R, Glymph T, Granato T, O'Connor C, Kollias L, Lanyon R.

Water Sci Technol. 2009;60(7):1847-55. doi: 10.2166/wst.2009.598.

PMID:
19809148
16.

Patient- and physician-rated measures demonstrate the effectiveness of ropinirole in the treatment of restless legs syndrome.

Kushida CA, Geyer J, Tolson JM, Asgharian A.

Clin Neuropharmacol. 2008 Sep-Oct;31(5):281-6. doi: 10.1097/WNF.0b013e31815a3eec.

PMID:
18836346
17.

Recognition, diagnosis, and treatment of restless legs syndrome.

Smith JE, Tolson JM.

J Am Acad Nurse Pract. 2008 Aug;20(8):396-401. doi: 10.1111/j.1745-7599.2008.00337.x. Review.

PMID:
18786013
18.

A green humidifier chamber.

Tolson J, Rochford P, Worsnop C.

Eur Respir J. 2008 Aug;32(2):533. doi: 10.1183/09031936.00046208. No abstract available.

19.

Making use of electronic data: the National Healthcare Safety Network eSurveillance Initiative.

Edwards JR, Pollock DA, Kupronis BA, Li W, Tolson JS, Peterson KD, Mincey RB, Horan TC.

Am J Infect Control. 2008 Apr;36(3 Suppl):S21-6. doi: 10.1016/j.ajic.2007.07.007. Review.

PMID:
18374208
20.

National Healthcare Safety Network (NHSN) Report, data summary for 2006, issued June 2007.

Edwards JR, Peterson KD, Andrus ML, Tolson JS, Goulding JS, Dudeck MA, Mincey RB, Pollock DA, Horan TC; NHSN Facilities.

Am J Infect Control. 2007 Jun;35(5):290-301. No abstract available.

PMID:
17577475
21.

Reading the abortion ruling.

Tolson J.

US News World Rep. 2007 Apr 30;142(15):36. No abstract available.

PMID:
17491476
22.

Is there room for the soul?

Tolson J.

US News World Rep. 2006 Oct 23;141(15):56-63. No abstract available.

PMID:
17432435
23.

Body weight distributions for risk assessment.

Portier K, Tolson JK, Roberts SM.

Risk Anal. 2007 Feb;27(1):11-26.

PMID:
17362397
24.

Cathepsin D is present in human eccrine sweat and involved in the postsecretory processing of the antimicrobial peptide DCD-1L.

Baechle D, Flad T, Cansier A, Steffen H, Schittek B, Tolson J, Herrmann T, Dihazi H, Beck A, Mueller GA, Mueller M, Stevanovic S, Garbe C, Mueller CA, Kalbacher H.

J Biol Chem. 2006 Mar 3;281(9):5406-15. Epub 2005 Dec 14.

25.

Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice.

Tolson JK, Dix DJ, Voellmy RW, Roberts SM.

Toxicol Appl Pharmacol. 2006 Jan 1;210(1-2):157-62. Epub 2005 Nov 8.

PMID:
16280147
26.

Differential detection of S100A8 in transitional cell carcinoma of the bladder by pair wise tissue proteomic and immunohistochemical analysis.

Tolson JP, Flad T, Gnau V, Dihazi H, Hennenlotter J, Beck A, Mueller GA, Kuczyk M, Mueller CA.

Proteomics. 2006 Jan;6(2):697-708.

PMID:
16252305
27.

Food and America. How America eats.

Tolson J, Hsu C, Wells P, Curry A, Ewers J, Shute N, Kulman L, Ewers J, Spake A, Gilgoff D, Querna B, Kelly K, Butler CK, Blake S, Hayden T, Pope V, Hsu C, Shute N, Andrews M, Eskin B, Nathan J.

US News World Rep. 2005 Aug 15-22;139(6):32-71. No abstract available.

PMID:
16114218
28.

Monitoring health care workers after smallpox vaccination: findings from the Hospital Smallpox Vaccination-Monitoring System.

Klevens RM, Kupronis BA, Lawton R, Joseph D, Richards C Jr, Abshire J, Barnes M, Cardo D, Curtis A, Edwards J, Gaines Y, Horan T, Jernigan J, Pearson M, Skaggs R, Sinkowitz-Cochran R, Solomon S, Stein G, Tokars J, Tolson J, Wages J; Hospital Smallpox Vaccination-Monitoring System Team.

Am J Infect Control. 2005 Aug;33(6):315-9.

PMID:
16110599
29.

HIV antiretroviral treatment: early versus later.

Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J.

J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):562-9.

PMID:
16044008
30.

Wrestling with the final call. When it comes to end-of-life decisions, taking an ethical path isn't always easy.

Tolson J.

US News World Rep. 2005 Apr 4;138(12):22-3. No abstract available.

PMID:
15825590
31.

Hard lessons.

Tolson J, Hallett V, Kingsbury A.

US News World Rep. 2005 Mar 7;138(8):30-6. No abstract available.

PMID:
15768528
32.

Manipulating heat shock protein expression in laboratory animals.

Tolson JK, Roberts SM.

Methods. 2005 Feb;35(2):149-57. Epub 2004 Dec 19.

PMID:
15649841
33.

Mass spectrometry meets medical sciences: making headway in molecular disease diagnostics.

Flad T, Tolson J.

Anal Bioanal Chem. 2005 Jan;381(1):24-7. No abstract available.

PMID:
15619085
34.

Heat shock proteins and acquired resistance to uranium nephrotoxicity.

Tolson JK, Roberts SM, Jortner B, Pomeroy M, Barber DS.

Toxicology. 2005 Jan 5;206(1):59-73.

PMID:
15590109
36.

Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients.

Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T.

Lab Invest. 2004 Jul;84(7):845-56. Erratum in: Lab Invest. 2004 Sep;84(9):1220-1.

37.
38.

Development of an MHC-class I peptide selection assay combining nanoparticle technology and matrix-assisted laser desorption/ionisation mass spectrometry.

Flad T, Schiestel T, Brunner H, Tolson J, Ouyang Q, Pawelec G, Mueller GA, Mueller CA, Tovar GE, Beck H.

J Immunol Methods. 2003 Dec;283(1-2):205-13.

PMID:
14659912
39.

Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.

Rawlings MK, Thompson MA, Farthing CF, Brown LS, Racine J, Scott RC, Crawford KH, Goodwin SD, Tolson JM, Williams VC, Shaefer MS; NZTA4006 Helping to Enhance Adherence to Antiretroviral Therapy (HEART) Study Team.

J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):174-83.

PMID:
14526206
40.

Does using a laparoscopic approach to cholecystectomy decrease the risk of surgical site infection?

Richards C, Edwards J, Culver D, Emori TG, Tolson J, Gaynes R; National Nosocomial Infections Surveillance (NNIS) System, Centers for Disease Control and Prevention.

Ann Surg. 2003 Mar;237(3):358-62.

41.

The ghost hunters.

Tolson J.

US News World Rep. 2002 Dec 16;133(23):44-6. No abstract available.

PMID:
12500722
42.

Patient-perceived barriers to antiretroviral adherence: associations with race.

Ferguson TF, Stewart KE, Funkhouser E, Tolson J, Westfall AO, Saag MS.

AIDS Care. 2002 Oct;14(5):607-17.

PMID:
12419110
43.

Detection of dermcidin-derived peptides in sweat by ProteinChip technology.

Flad T, Bogumil R, Tolson J, Schittek B, Garbe C, Deeg M, Mueller CA, Kalbacher H.

J Immunol Methods. 2002 Dec 1;270(1):53-62.

PMID:
12379338
44.

Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF; Intercompany Collaboration for AIDS Drug Development Protocol 604 Team.

J Infect Dis. 2002 Oct 1;186(7):1028-33. Epub 2002 Sep 13. Erratum in: J Infect Dis 2002 Dec 15;186(12):1872.

PMID:
12232846
45.

Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.

Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, Saag MS.

AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):909-16.

PMID:
12230934
46.

Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999.

Richards C, Emori TG, Edwards J, Fridkin S, Tolson J, Gaynes R.

Am J Infect Control. 2001 Dec;29(6):400-3.

PMID:
11743488
47.

Correlation between self-reported adherence to highly active antiretroviral therapy (HAART) and virologic outcome.

DeMasi RA, Graham NM, Tolson JM, Pham SV, Capuano GA, Fisher RL, Shaefer MS, Pakes GE, Sawyerr GA, Eron JJ Jr.

Adv Ther. 2001 Jul-Aug;18(4):163-73.

PMID:
11697019
48.

Impact of HIV type 1 drug resistance mutations and phenotypic resistance profile on virologic response to salvage therapy.

Ross L, Liao Q, Gao H, Pham S, Tolson J, Hertogs K, Larder B, Saag MS.

AIDS Res Hum Retroviruses. 2001 Oct 10;17(15):1379-85.

PMID:
11679150
49.

Surgical site infection (SSI) rates in the United States, 1992-1998: the National Nosocomial Infections Surveillance System basic SSI risk index.

Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS.

Clin Infect Dis. 2001 Sep 1;33 Suppl 2:S69-77.

PMID:
11486302
50.

Feeding back surveillance data to prevent hospital-acquired infections.

Gaynes R, Richards C, Edwards J, Emori TG, Horan T, Alonso-Echanove J, Fridkin S, Lawton R, Peavy G, Tolson J.

Emerg Infect Dis. 2001 Mar-Apr;7(2):295-8.

Supplemental Content

Loading ...
Support Center